METTL16 and pancreatic ductal adenocarcinoma: This phosphorylation-dependent regulatory mechanism underscores METTL16's dual role in maintaining genome stability and its potential as a therapeutic target in HR repair-deficient cancers, including pancreatic ductal adenocarcinoma.60